Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
DDX17 N/A
Sequence Length (AA) Molecular Weight (Da)
729 80272
Protein Name
Probable ATP-dependent RNA helicase DDX17
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MPTGFVAPIL CVLLPSPTRE AATVASATGD SASERESAAP AAAPTAEAPP
60 70 80 90 100
PSVVTRPEPQ ALPSPAIRAP LPDLYPFGTM RGGGFGDRDR DRDRGGFGAR
110 120 130 140 150
GGGGLPPKKF GNPGERLRKK KWDLSELPKF EKNFYVEHPE VARLTPYEVD
160 170 180 190 200
ELRRKKEITV RGGDVCPKPV FAFHHANFPQ YVMDVLMDQH FTEPTPIQCQ
210 220 230 240 250
GFPLALSGRD MVGIAQTGSG KTLAYLLPAI VHINHQPYLE RGDGPICLVL
260 270 280 290 300
APTRELAQQV QQVADDYGKC SRLKSTCIYG GAPKGPQIRD LERGVEICIA
310 320 330 340 350
TPGRLIDFLE SGKTNLRRCT YLVLDEADRM LDMGFEPQIR KIVDQIRPDR
360 370 380 390 400
QTLMWSATWP KEVRQLAEDF LRDYTQINVG NLELSANHNI LQIVDVCMES
410 420 430 440 450
EKDHKLIQLM EEIMAEKENK TIIFVETKRR CDDLTRRMRR DGWPAMCIHG
460 470 480 490 500
DKSQPERDWV LNEFRSGKAP ILIATDVASR GLDVEDVKFV INYDYPNSSE
510 520 530 540 550
DYVHRIGRTA RSTNKGTAYT FFTPGNLKQA RELIKVLEEA NQAINPKLMQ
560 570 580 590 600
LVDHRGGGGG GGGRSRYRTT SSANNPNLMY QDECDRRLRG VKDGGRRDSA
610 620 630 640 650
SYRDRSETDR AGYANGSGYG SPNSAFGAQA GQYTYGQGTY GAAAYGTSSY
660 670 680 690 700
TAQEYGAGTY GASSTTSTGR SSQSSSQQFS GIGRSGQQPQ PLMSQQFAQP
710 720 729
PGATNMIGYM GQTAYQYPPP PPPPPPSRK

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-352 Collapse assay details

Data source: Panorama

Official Gene Symbol
DDX17
Peptide Sequence
DWVLNEFR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
458
Peptide End
465
CPTAC ID
CPTAC-352
Peptide Molecular Mass
1,077.5243
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
cell line lysate pool
Submitting Laboratory
Broad Institute and FHCRC
Submitting Lab PI
Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C,15N
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y6 (1+) 10.5 6.9 5.5 12.1 15.9 7.6 16 17.3 9.4 25 15 15
y5 (1+) 12.4 11.9 10.2 16.1 20.1 13 20.3 23.4 16.5 25 15 15
y4 (1+) 18.5 10.5 5.6 22.8 19.5 6.6 29.4 22.1 8.7 25 15 15
sum 9.2 8.1 6.9 11.5 17 8.5 14.7 18.8 10.9 25 15 15


Additional Resources and Comments


Assay Details for CPTAC-351 Collapse assay details

Data source: Panorama

Official Gene Symbol
DDX17
Peptide Sequence
ELAQQVQQVADDYGK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
255
Peptide End
269
CPTAC ID
CPTAC-351
Peptide Molecular Mass
1,690.8162
Species
Homo sapiens (Human)
Assay Type
Direct MRM
Matrix
cell line lysate pool
Submitting Laboratory
Broad Institute and FHCRC
Submitting Lab PI
Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C,15N
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y10 (1+) 12.6 7.7 5.2 19.8 8.7 8.4 23.5 11.6 9.9 25 15 15
y9 (1+) 16.1 6.1 5.9 18.1 7.9 6.2 24.2 10 8.6 25 15 15
y8 (1+) 23.4 4.6 4.7 25.8 6.2 5.3 34.8 7.7 7.1 25 15 15
sum 8.8 5.6 4.4 14.7 5.9 5.3 17.1 8.1 6.9 25 15 15


Additional Resources and Comments